诚信认证：
工商注册信息已核实！
VX-809 (Lumacaftor)
| 品牌 | 厂商性质 | 产地 | 货期 |
|---|---|---|---|
| 阿拉丁 | 生产商 | 上海 | 现货 |
| 货号 | CAS号 | 操作 |
|---|---|---|
| V127916-5mg | 936727-05-8 | 询价 |
| V127916-10mg | 936727-05-8 | 询价 |
| V127916-50mg | 936727-05-8 | 询价 |
- 分子式 C24H18F2N2O5
- 分子量452.41
属性
| 溶解性 |
|
| 存贮条件 | 储存温度-20°C |
描述
| 产品介绍 | VX-809 (Lumacaftor)通过促进突变型CFTR(F508del-CFTR)的成熟，从而纠正常见于囊性纤维化的CFTR突变，EC50为0.1 μM。 |
| 备注 | VX-809 acts to correct CFTR mutations common in cystic fibrosis by increasing mutant CFTR (F508del-CFTR) maturation,EC50 of 0.1 μM. Phase 3. |
| 生化机理 |
VX-809 is the second investigational oral candidate compound for the treatment of cystic fibrosis (CF). VX-809 may act to restore the function of the cystic fibrosis transmembrane conductance regulator (CFTR) protein, the defective cell membrane protein responsible for the progression of CF. VX-809 defects in the CFTR protein affect the transport of chloride and other ions across cells, and lead to the accumulation of thick, sticky mucus in the lungs of patients with CF. This mucus fosters chronic infection and inflammation, and results in irreversible lung damage. |
| 别名 | VX 809; 3-[6-[[[1-(2,2-二氟-1,3-苯并二氧戊环-5-基)环丙基]羰基]氨基]-3-甲基-2-吡啶基]苯甲酸;VX 809; VX809; Lumacaftor; VRT 826809;3-[6-[[[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)cyclopropyl]carbonyl]amino]-3-methyl-2-pyridinyl]benzoic acid |
VX-809 (Lumacaftor)信息由上海阿拉丁生化科技股份有限公司为您提供，如您想了解更多关于VX-809 (Lumacaftor)报价、型号、参数等信息，欢迎来电或留言咨询。
注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途